The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Open accessAbstract
Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–245 of 245
Hepatic DPP4 DNA Methylation Associates With Fatty Liver
Baumeier, C., Saussenthaler, S., Kammel, A., Jähnert, M., Schlüter, L., Hesse, D., Canouil, M., Lobbens, S., Caiazzo, R. J., Raverdy, V., et al. (2016) · Diabetes · doi:10.2337/db15-1716 · Cited by 89
Chronic Hepatitis C in Alcoholic Patients: Prevalence, Genotypes, and Correlation to Liver Disease
Befrits, R., Hedman, M., Blomquist, L., Allander, T., Grillner, L., Kinnman, N., Rubio‐Terres, C., & Hultcrantz, R. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509101616 · Cited by 85
Rossi, R. E., Conte, D., & Massironi, S. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.05.021 · Cited by 85
Nishimoto, A. T., Usery, J. B., Winton, J. C., & Twilla, J. D. (2017) · In Vivo · doi:10.21873/invivo.11034 · Cited by 85
Testino, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14642 · Cited by 84
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Kenna, G. A., Lomastro, T., Schiesl, A., Leggio, L., & Swift, R. M. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902020135 · Cited by 78
Chamorro, A. ‐., Torres, J. L., Mirón‐Canelo, J. ‐., González‐Sarmiento, R., Laso, F. J., & Marcos, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12890 · Cited by 76
Caballería, J., Parés, A. R., Brú, C., Mercader, J., García-Plaza, A., Caballería, L., Clemente, G., Rodrigo, L., & Rodés, J. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80202-x · Cited by 74
S-Adenosyl-l-methionine and alcoholic liver disease in animal models
Lieber, C. S. (2002) · Alcohol · doi:10.1016/s0741-8329(02)00230-6 · Cited by 73
Kim, S. J., Jung, Y. S., Kwon, D. Y., & Kim, Y. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.003 · Cited by 71
Current Management of Alcoholic Hepatitis and Future Therapies
Saberi, B., Dadabhai, A. S., Jang, Y.-Y., Gurakar, A. O., & Mezey, E. (2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00006 · Cited by 70
Gege, C., Kinzel, O., Steeneck, C., Schulz, A., & Kremoser, C. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141112094430 · Cited by 69
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
Pencek, R., Marmon, T., Roth, J. D., Liberman, A., Hooshmand-Rad, R., & Young, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12681 · Cited by 67
Laskar, M. G., Eriksson, M., Rudling, M. J., & Angelin, B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12594 · Cited by 67
Inagaki, T. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00147 · Cited by 61
Alcoholic liver disease and hepatitis C virus infection
Novo‐Veleiro, I., Alvela-Suárez, L., Chamorro, A.-J., González-Sarmiento, R., Laso, F.-J., & Marcos, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i4.1411 · Cited by 60
Chen, C. M., Yoon, Y., Yi, H., & Lucas, D. L. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00304.x · Cited by 57
Zeng, T., Zhang, C., Zhao, X., & Xie, K.-Q. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000068 · Cited by 53
Liu, X., Zhang, P., Martin, R. C. G., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., & Li, Y. (2016) · PubMed · Cited by 52
Pharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, C. L., Halse, M., Leggio, L., Fricchione, S. B., Brickley, M., Haass-Koffler, C. L., Tavares, T., Swift, R. M., & Kenna, G. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140028 · Cited by 51
Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
Tilg, H., & Moschen, A. R. (2010) · PubMed · Cited by 48
Assy, N., Grozovski, M., Bersudsky, I., Szvalb, S., & Hussein, O. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i27.4369 · Cited by 48
The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease
Akyüz, F., Demır, K., Özdil, S., Aksoy, N., Poturoğlu, Ş., İbrişim, D., Kaymakoğlu, S., Besisik, F. S., Boztaş, G., Çakaloğlu, Y., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9145-x · Cited by 48
Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems
Tsui, J. I., Pletcher, M. J., Vittinghoff, E., Seal, K. H., & Gonzales, R. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.027 · Cited by 47
Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
Makri, E. S., Cholongitas, Ε., & Τζιόμαλος, Κ. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9039 · Cited by 45
Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics
Ismail, A., Fouad, O., Abdelnasser, A., Chowdhury, A., & Selim, A. (2009) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-009-9092-9 · Cited by 44
Duman, D., Özdemir, F. T., Birben, E., Keskin, O., Ekşioğlu, E., Çelikel, Ç., Kalaycı, Ö., & Kalaycı, C. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9723-y · Cited by 41
Outcomes of residential treatment of substance abuse in hospital- and community-based programs
Moos, R. H., King, M. J., & Patterson, M. (1996) · Psychiatric Services · doi:10.1176/ps.47.1.68 · Cited by 37
Støy, S. H., Sandahl, T. D., Dige, A. K., Agnholt, J. S., Rasmussen, T. K., Grønbæk, H., Deleuran, B. W., & Vilstrup, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055101 · Cited by 35
An overview of the genetics, mechanisms and management of NAFLD and ALD
Rowell, R., & Anstee, Q. M. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s77 · Cited by 35
Al-Gayyar, M. M. H., Shams, M. E. E., & Barakat, E. A. M. E. (2011) · Pharmaceutical Biology · doi:10.3109/13880209.2011.604088 · Cited by 31
Controversies in the Management of Alcoholic Liver Disease
Tan, H., Virmani, S., & Martin, P. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20135 · Cited by 31
Adams, L. A. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.08695.x · Cited by 31
Shiffman, M. L., Freilich, B. L., Vuppalanchi, R., Watt, K. D. S., Burgess, G., Morris, M., Sheedy, B., & Schiff, E. R. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30191-4 · Cited by 31
Nonalcoholic fatty liver disease and bariatric surgery
Stephen, S., Baranova, A. V., & Younossi, Z. M. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.97 · Cited by 30
Itou, M., Kawaguchi, T., Taniguchi, E., Oriishi, T., & Sata, M. (2012) · Case Reports in Gastroenterology · doi:10.1159/000341510 · Cited by 30
Understanding and Treating Patients With Alcoholic Cirrhosis: An Update
Addolorato, G., Russell, M., Albano, E., Haber, P., Wands, J. R., & Leggio, L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00956.x · Cited by 29
Chemokines and alcoholic hepatitis: are chemokines good therapeutic targets?
Gao, B., & Xu, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306603 · Cited by 27
Haga, S., Yimin, & Ozaki, M. (2017) · BMC Gastroenterology · doi:10.1186/s12876-016-0568-3 · Cited by 25
Hepatic-specific PPARα-FGF21 action in NAFLD
Piccinin, E., & Moschetta, A. (2016) · Gut · doi:10.1136/gutjnl-2016-311408 · Cited by 22
Practical Concerns and Controversies in the Management of Alcoholic Hepatitis.
Im, G. Y., & Lucey, M. R. (2016) · PubMed · Cited by 15
Management of Alcoholic Liver Disease: An Update
Kershenobich, D., Lau-Corona, D., Kershenovich, R., & Gutiérrez‐Reyes, G. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01402.x · Cited by 6
Cited by
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Apoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582
Beneficial Effects of Betaine: A Comprehensive Review
Arumugam, M. K., Paal, M. C., Donohue, T. M., Ganesan, M., Osna, N. A., & Kharbanda, K. K. (2021) · Biology · doi:10.3390/biology10060456 · Cited by 291
Self-citationBenedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331460 · Cited by 242
“132 MASLD management is a complex condition associated with factors like obesity, arterial hypertension, IR, and abnormal lipid profiles, that typically requires an intricate intervention once diagnosed.”
BackgroundLeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“Other than what has already been mentioned, interventions for MASLD [ 351 ] N u t r iti on a l s uppo r t: V it a m i n s li k e f o l a t e , v it a m i n B 6 , v it a m i n B 12 , v it a - m i n A , a nd t h i a m i n e [ 351 ] M i n e r a l s ( li k e s e l e n i u m , z i n c , c opp e r , a nd…”
BackgroundInfluential
Metadata
- Authors
- Singh, S., Osna, N. A., & Kharbanda, K. K.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2017-09-28
- Volume
- 23
- Issue
- 36
- Pages
- 6549-6570
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2758047358
- Cited by
- 257
- References
- 245
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.